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Abstract
Background: Fascin-1 is an actin-bundling protein expressed in many human carcinomas, although absent from
most normal epithelia. Fascin-1 promotes filopodia formation, migration and invasion in carcinoma cells; in mouse
xenograft tumor models it contributes to metastasis. Fascin-1 is an interesting candidate biomarker for aggressive,
metastatic carcinomas but data from individual studies of human tumors have not yet been pooled systematically.
Methods: This systematic review was conducted in accordance with PRISMA guidelines, using fixed and random
effects models, as appropriate, to undertake meta-analysis.
Results: A total of 26 immunohistochemical studies of 5 prevalent human carcinomas were identified for meta-analysis.
Fascin-1 was associated with increased risk of mortality for breast (pooled hazard ratio, (HR) = 2.58; 95% confidence
interval (CI) 1.48 to 4.52; P = 0.001), colorectal (HR = 1.60 (1.37 to 1.86; P <0.001) and esophageal carcinomas (HR = 1.35;
CI 1.13 to 1.60; P = 0.001). There was no evidence of association of fascin-1 with mortality in gastric and lung
carcinomas. Fascin-1 was associated with increased risk of disease progression in breast (HR = 2.48; CI 1.38 to 4.46;
P = 0.002) and colorectal carcinomas (HR = 2.12; CI 1.00 to 4.47; P = 0.05), but not with progression of lung carcinomas
(HR = 0.95; CI 0.49 to 1.85; P = 0.9). Fascin-1 was associated with increased risk of lymph node metastasis in colorectal
(pooled risk ratio (RR) = 1.47; CI 1.26 to 1.71; P <0.001) and gastric carcinomas (RR = 1.43; CI 1.21 to 1.70; P <0.001). There
was no evidence of association of fascin-1 with lymph node metastasis in lung or esophageal carcinomas. Fascin-1 was
associated with increased risk of distant metastasis in colorectal (RR = 1.70; CI 1.18 to 2.45; P = 0.004) and gastric
carcinomas (RR = 1.93; CI 1.21 to 3.33; P = 0.02). No association with distant metastasis in esophageal carcinomas was
observed. Pooling across all the carcinomas provided strong evidence for association of fascin-1 with increased risk of
mortality (HR = 1.44; CI 1.24 to 1.68; P <0.001; n = 3,645), lymph node metastasis (RR = 1.36; CI 1.18 to 1.55; P <0.001;
n = 2,906) and distant metastasis (1.76; 1.34 to 2.32; P <0.001; n = 1,514).
Conclusions: Fascin-1 is associated consistently with increased risk of mortality in breast, colorectal and
esophageal carcinomas and with metastasis in colorectal and gastric carcinomas. The results were stable to various
sensitivity analyses and did not vary by predefined subgroups. These data will assist rational decision making for
focusing investigations of fascin-1 as a biomarker or therapeutic target onto the most relevant carcinomas.
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Background
Biomarkers have a pivotal role in cancer screening, diag-
nosis, prognosis and therapeutic monitoring. Since
tumor metastasis remains a major cause of cancer mor-
tality, there is a compelling need for the discovery and
validation of novel biomarkers for early characterization
of carcinomas by their aggressive potential [1].
Over the last 10 years, in vitro, in vivo and clinical
immunohistochemical studies have implicated fascin-1 as
a novel candidate biomarker for aggressive carcinomas of
the biliary duct, bladder, brain, breast, colorectum, endo-
metrium, kidney, liver, lung, neck, esophagus, pharynx,
ovary, pancreas, prostate and stomach [2-4]. Fascin-1 is a
55-kDa, actin-bundling protein that plays a key role in the
assembly and stability of cell protrusions and other actin-
based structures that aid in cell motility, migration and
invasion [2,4]. In normal epithelia, fascin-1 is usually
absent or present at low levels, yet its expression is
increased in colorectal adenomas, esophageal dysplasia
and in many carcinomas [2-8]. Fascin-1 increases the
migratory capacity of carcinoma cells in culture [9-12];
this is associated with increased invasive and metastatic
potential in mouse tumor xenograft models [10-13]. These
effects are considered to underlie the observed correlation
between fascin-1 expression and clinical aggressiveness in
human carcinomas [2-4]. Fascin-1 was recently implicated
as the binding partner of the metastasis inhibitory small
molecule, macroketone, and this has further increased
interest in its potential as a therapeutic target [13,14].
Given the temporal and financial commitments needed
to translate basic research to the clinic, it is important to
evaluate candidate biomarkers or targets thoroughly at an
early stage. Several studies [13,15-17] have investigated the
clinical relevance of fascin-1 mRNA levels in tumor tis-
sues. For breast carcinomas, it was reported that high fas-
cin-1 mRNA levels were associated with a lung metastasis
signature [16] and decreased overall and metastasis- free
survival [13]. However, tissue mRNA is not well-suited to
examine the expression of fascin-1 in tumors, because the
extracted mRNAs derive from a mixture of cells including
myofibroblasts, endothelial cells and dendritic cells that
express fascin-1 constitutively [18]. Many immunohisto-
chemical studies of fascin-1 protein in carcinomas have
been published. The majority of these immunohistochem-
ical studies have correlated fascin-1 protein in the primary
tumor with poor prognosis; however, it is not yet clear if
fascin-1 has independent value as a biomarker as the indi-
vidual studies are not always consistent. For example,
immunohistochemical studies of breast carcinomas have
reached discrepant conclusions on its association with
mortality and metastasis [19-22]. Immunohistochemistry
is a complex metric for meta-analysis, due to the use of
different scoring systems to assess the extent of fascin-1
staining in tumor specimens, yet studies of fascin-1 have
the advantage that almost all publications to date have
used the same two antibodies to fascin-1.
To evaluate the hypothesis that fascin-1 can serve as
an early marker for identification of the most aggressive
carcinomas with metastatic potential, we have con-
ducted a systematic review and meta-analysis of studies
that have investigated the clinical implication of fascin-1
in carcinoma progression and patient mortality by
immunohistochemistry.
Methods
Inclusion and exclusion criteria
A systematic review of all published literature on the
association of fascin-1 protein expression with carci-
noma progression in breast, colorectal, gastric, lung and
esophageal carcinomas was carried out. We focused on
these carcinomas because they are the most prevalent
carcinomas that are major sources of morbidity and
mortality worldwide [23].
Studies had to meet the following inclusion criteria:
(1), either randomized controlled trials, cohort or case-
control studies; (2), in humans with carcinomas of
the breast, colorectum, stomach, lung or esophagus;
(3), detected fascin-1 by immunohistochemistry and com-
pared high versus low fascin-1 staining; negative versus
positive fascin-1 staining; or negative, low and high fascin-
1 staining, and, (4), reported data for at least one of the
following outcomes: lymph-node or distal metastasis, dis-
ease progression or mortality. We excluded studies investi-
gating tissue mRNA because the extracted mRNAs derive
from a mixture of cells including myofibroblasts, endothe-
lial cells and dendritic cells that express fascin-1 constitu-
tively [18]. We excluded case reports, animal and in vitro
studies.
Data sources
We searched the Medline, Embase, Web of Science and
PubMed bibliographic databases from their inception until
April 2012, using a combined text word and MeSH head-
ing search strategy (see Additional file 1 for search terms).
We also searched the reference lists of relevant articles
and reviews [2-4]. We did not contact any organizations
to obtain unpublished results and we did not identify any
on-going studies from our systematic review. Authors of
conference abstracts were contacted for the published
report. We did not apply any language restrictions.
Selection of studies
The title and abstracts of all retrieved papers were then
assessed using the pre-specified inclusion criteria by one
author (VYT). Where abstracts were not available or
when eligibility was unclear based on the abstract, the
full papers were obtained and assessed. Some studies
were excluded on the basis of the title or abstract; for all
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others, full papers were obtained and reviewed by two
independent assessors (VYT, RMM), with each assessor
blind to the decision of the other. Discrepancies in assign-
ing studies as eligible were resolved by mutual agreement
and discussion with JCA. We identified duplicate publica-
tions by reviewing study name, authors, location, study
population, dates and study design. For multiple study
publications from the same patient cohort reporting on
similar outcomes, we chose the study with the largest
number of cases. For studies that presented different out-
comes, we extracted outcomes from both publications.
Data extraction
Data were extracted onto standardized pro forma by one
assessor (VYT) and then double-checked by two others
(RMM and SJL). Data were extracted on year of publica-
tion, study size, mean or median age of patients, location
and study design. Different semi-quantitative parameters
were used to categorize and dichotomize fascin-1 stain-
ing (see Additional file 1 for alternative categorization
methods used to assess immunohistochemical staining of
fascin-1). Data were extracted on fascin-1 scoring and
categorization, the total number of patients in each fas-
cin-1 category and total number of patients experiencing
each outcome by fascin-1 category.
For dichotomous outcomes (that is, lymph node metas-
tasis and distant metastasis), the number of patients with
the event of interest and total number of patients in each
category group (that is, high, low, positive or negative
expression) were extracted and the data used to compute
risk ratios. If separate data for immunoreactivity or inten-
sity scores were given, we chose to extract the immunor-
eactivity scores. This is because a recent study [24]
showed that immunoreactivity scores alone are a suffi-
cient measure for estimating the association of fascin-1
with mortality. For time to event outcomes (that is, mor-
tality and time-to-disease progression), a hazard ratio
was extracted from the study report where possible,
otherwise a hazard ratio was estimated from Kaplan
Meier curves using the method of Tierney et al. [25]
(described in Additional file 1). For data extracted from
Kaplan-Meier curves, we attempted to check the result
with the authors, as there is a potential to overestimate
the true number of events [26]. For studies that did not
provide a clear definition of their outcomes for time-to-
disease progression analysis, we assumed that disease
progression was calculated from the date of surgery to
the date of disease progression (which is a binary out-
come indicating occurrence of mortality, recurrence or
metastasis). For time-to-disease progression analysis, a
positive hazard ratio (HR) implies an increased risk
of disease progression. When a measure of effect (for
example, hazard ratio) was adjusted for covariates, it was
also extracted along with details of the corresponding
covariates.
Where studies included results for each of normal tis-
sue, precursor lesions and carcinomas, we extracted data
on fascin-1 in the carcinomas only. For papers or con-
ference abstracts where data were missing or not clear,
authors were contacted requesting further information
that would enable us to include their data in our meta-
analysis. Any disagreements on values of data items
extracted were resolved by discussion among VYT,
RMM and JCA, or by attempting to contact the authors
of the papers for clarification.
Quality of studies
The methodological quality of studies which presented
mortality data was judged and agreed to by three assessors
(RMM, SJL and VYT) using the Newcastle-Ottawa scale
[27], which was developed to assess the quality of non-ran-
domized cohort studies in meta-analysis. The studies are
judged on three broad perspectives using a nine-point
scale: the selection of the study group (0 to 4 points), com-
parability of cohorts (0 to 2 points) and ascertainment of
outcome (0 to 3 points).
Statistical analysis
For our meta-analysis, we stratified the results by method
of scoring (that is, low versus high or positive versus
negative) and by type of carcinoma. We used the metan
command in Stata (StataCorp. 2009. Stata Statistical Soft-
ware: release 11.2. StataCorp LP; College Station, TX,
USA) to calculate a summary hazard ratio (HR) for mor-
tality and time-to-disease progression outcomes or a
summary risk ratio (RR) for lymph node and distant
metastasis outcomes. We combined fully adjusted effect-
estimates if these were available; otherwise, we used the
unadjusted estimates.
Heterogeneity was assessed by performing Cochran’s Q
test. The I2 statistic was calculated as a quantitative mea-
sure of the degree of inconsistency across studies, where
0% indicates no heterogeneity and larger percentages indi-
cate increasing heterogeneity [28]. For consistency of
presentation throughout our paper, an I2 value of 0 is con-
sidered no heterogeneity, an I2 value of 1 to 25% is consid-
ered low heterogeneity, an I2 value of 25 to 75% is
considered moderate heterogeneity and an I2 value of 75
to 100% is considered as high heterogeneity. We per-
formed fixed-effects meta-analysis unless there was appre-
ciable heterogeneity (I2 value over 50% or chi-squared
P-value less than 0.1), in which case we also performed a
random-effects meta-analysis, which relaxes the assump-
tion of a common treatment effect (that is, effect sizes are
assumed to have a normal distribution with variance τ2,
based on Cochran’s Q statistic for heterogeneity).
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Subgroup analysis by strata of methodological quality
scores (≥6 points, 5 points, <5 points) was carried out to
assess whether differences in the quality of the studies
were a potential source of heterogeneity for each outcome.
Another possible source of heterogeneity was assessed by
carrying out subgroup analysis for studies which presented
adjusted hazard ratios from multivariable models and for
those which presented only unadjusted results.
Sensitivity analysis was carried out for studies which
provided a clear definition that mortality referred to
death from cancer. For the studies of colorectal carcino-
mas, sensitivity analysis was carried out for studies which
had included an analysis of patients with stage III/IV col-
orectal carcinomas in their results. Small-study effects
were assessed for each outcome by visual inspection of
the funnel plot and an Egger’s test [29].
Results
Identification and selection of included studies
The literature search retrieved a total of 3,098 studies,
including 2,062 from MEDLINE, 541 from Embase, 392
from Web of Science and 103 from PubMed. A total of
48 papers were classified initially as potentially relevant
and the full papers retrieved. Twenty-two potentially
relevant papers were excluded for the following reasons:
compared fascin-1 in normal tissues versus tumors in the
same patients [30,31]; carried out studies in adenomas
[5], pleomorphic carcinomas [32], or neuroendocrine
tumors [33]; did not report on relevant exposure [34];
did not present outcomes on mortality, progression or
metastasis [35-39]; did not present results for mortality
or metastasis [22,40-43]; duplicate abstract or study
[44-47], and inability to categorize fascin-1 expression
[48]. We were unable to obtain one paper either electro-
nically or after contacting the authors [49]. Overall,
26 papers published between 2003 and 2011 were
included in our meta-analysis (Figure 1).
Characteristics of included studies
Only one study [24] involved a prospectively assembled
cohort while the remainder studied retrospectively
assembled cohorts. The median sample size of the studies
was 128.5 (range 46 to 509) cases, but no studies provided
a sample size or power calculation. The characteristics and
key results of these studies, as published, are shown in
Additional file 2.
Quality of studies
The methodological quality of the papers was assessed
using the Newcastle-Ottawa scaling method [27]. For
the 18 studies [6,7,9,19-21,24,50-60] which examined
the association of fascin-1 with mortality, 8 studies
[6,7,9,24,52,55,56,58] were found to be of high methodolo-
gical quality (Newcastle-Ottawa scores of above 6 points),
2 studies [50,51] had a score of 5 points which is just
below the threshold for high methodological quality and 8
studies [19-21,53,54,57,59,60] were of poor methodological
quality (Additional file 1).
For the 6 studies [19,21,50-53] which examined the
association of fascin-1 with time-to-disease progression,
1 study [52] was of high methodological quality, 2 studies
[50,51] had quality scores just below the ‘high’ threshold
and 3 studies [19,21,53] were of poor methodological
quality (Additional file 1).
For the 17 studies [6-9,11,54-58,60-66] that examined
the association of fascin-1 with lymph node metastasis,
6 studies [6,7,9,55,56,58] were of high methodological
quality and 11 studies [8,11,54,57,60-66] were of poor
methodological quality (Additional file 1).
For the 9 studies [8,9,11,52,54,55,57,58,61] which exam-
ined the association of fascin-1 with distant metastasis,
4 studies [9,52,55,58] were of high methodological quality
and 5 studies [8,11,54,57,61] were of poor methodological
quality (Additional file 1).
Meta-analysis results
Breast carcinoma
Three studies [19-21] examined the association of fascin-1
with mortality, with a total of 489 breast carcinoma cases.
The pooled fixed effects HR estimate for fascin-1 positivity
(that is, scored as positive versus negative) of the carcino-
mas was 2.58 (1.48 to 4.52; P = 0.001) (Figure 2A). There
was moderate heterogeneity between the three cohort stu-
dies (I2 = 31.4%), although the statistical evidence support-
ing heterogeneity was weak (P = 0.23).
Two studies [19,21] examined the association of fascin-1
positivity of carcinomas with time-to-disease progression,
with a total of 281 breast carcinoma cases. Based on stu-
dies examining fascin-1 positivity, the pooled fixed effects
HR estimate was 2.48 (1.38 to 4.46; P = 0.002) for mortal-
ity, recurrence or metastasis outcomes (Figure 3). There
was low heterogeneity between the two cohort studies
(I2 = 17.4%; P = 0.27).
Colorectal carcinoma
Two studies [51,52] examined the association of fascin-1
positivity of carcinomas with mortality, and three [6,24,54]
examined the association of high fascin-1 with mortality,
with a total of 1,141 colorectal carcinoma cases. The study
by Ozerhan et al. [61] was excluded from the analysis as it
had presented two-year mortality rates for each fascin-1
category, and we could not estimate hazard ratios. For stu-
dies examining fascin-1 positivity of the carcinomas, the
pooled fixed effects HR estimate was 1.95 (1.32 to 2.87;
P = 0.001) (Figure 2A). Based on studies examining high
fascin-1 expression, the pooled fixed effects HR estimate
was 1.54 (1.3 to 1.82; P <0.001) (Figure 2B). Pooling across
all studies gave a pooled fixed effects HR estimate of 1.60
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(1.37 to 1.86; P <0.001). There was moderate heterogeneity
between studies that scored fascin-1 as positive versus
negative (I2 = 46.7%; P = 0.17). There was no heterogene-
ity between studies that scored fascin-1 as high vs low
levels (I2 = 0%; P = 0.64) or when all studies were pooled
(I2 = 0.0%; P = 0.41).
Two studies [51,52] examined the association of fascin-1
positivity of carcinomas with time-to-disease progression,
with a total of 354 colorectal carcinoma cases. Based on
studies examining fascin-1 positivity, the pooled random
effects HR estimate was 2.12 (1.00 to 4.47; P = 0.05) for
mortality, recurrence or metastasis outcomes (Figure 3).
There was moderate-to-high heterogeneity between the
two cohort studies (I2 = 73%; P = 0.06).
Three studies [11,61,62] examined the association of fas-
cin-1 positivity of colorectal carcinomas with lymph node
metastasis and 3 [6,54,63] examined the association of
high fascin-1 with lymph node metastasis, with a total of
833 colorectal carcinoma cases. Based on studies examin-
ing fascin-1 positivity, the pooled fixed effects RR estimate
was 1.64 (1.34 to 2.01; P <0.001) (Figure 4A). Based on
studies examining high fascin-1 expression, the pooled
fixed effects RR estimate was 1.28 (1.01 to 1.61; P = 0.04)
(Figure 4B). Pooling across all studies gave a pooled fixed
effects RR estimate of 1.47 (1.26 to 1.71; P <0.001). There
was no heterogeneity between studies that scored fascin-1
as positive versus negative (I2 = 0%, P = 0.4), high versus
low levels (I2 = 0%, P = 0.6) or when all studies were
pooled (I2 = 6.4%; P = 0.38).
Three studies [11,52,61] examined the association of fas-
cin-1 positivity of carcinomas with distant metastasis and
one [54] examined the association of high fascin-1 with
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patients [30,31] (n=2) 
? Carried out studies in adenomas [5] (n=1), pleomorphic 
carcinomas [32] (n=1), or neuroendocrine tumours [33] (n=1) 
? Did not report on relevant exposure [34] (n=1) 
? Did not present outcomes on mortality, time-to-progression or 
metastasis [35-39] (n=5) 
? Did not present results for mortality or metastasis [22,40-43] (n=5) 
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? Unable to obtain one paper either electronically or after 
contacting the authors [49] (n=1) 
Figure 1 Flow diagram of the systematic review and meta-analysis process.
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distant metastasis, with a total of 684 colorectal carcinoma
cases. The study by Oh et al. [51] was excluded from the
meta-analysis as it had presented adjusted HRs and could
not be pooled with the RRs estimated in the above studies.
Based on studies examining fascin-1 positivity, the pooled
fixed effects RR estimate was 1.72 (1.17 to 2.52; P = 0.006)
(Figure 5A). The study examining high fascin-1 had a RR
estimate of 1.56 (0.49 to 4.96; P =0.4) (Figure 5B). Pooling
across all studies gave a fixed effects RR estimate of 1.70
(1.18 to 2.45; P = 0.004). There was no heterogeneity
between studies that scored fascin-1 as positive versus
negative (I2 = 0%; P = 0.65) or when all studies were
pooled (I2 = 0%; P = 0.83).
Gastric carcinoma
Three studies [55-57] examined the association of fascin-1
positivity of carcinomas with mortality, with a total of 750
gastric carcinoma cases. Based on the studies, the pooled
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Figure 2 The association of fascin-1 with mortality in breast, colorectal, gastric, lung and esophageal carcinomas. The Forest plots
show (A) Positive versus negative = positive fascin-1 staining versus negative fascin-1 staining; (B) High versus low = High fascin-1 staining
versus low fascin-1 staining (see Methods for details of the scoring categorizations). In both A and B, squares indicate the study-specific effect
estimate, with the size proportional to the inverse of the variance (I-V); horizontal lines show study-specific 95% confidence intervals. The
diamonds are pooled estimates and their 95% confidence intervals, based on random or fixed effects meta-analysis models. The dashed vertical
line is the overall pooled estimate across all included studies and carcinomas.
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fixed effects HR estimate was 1.16 (0.86 to 1.56; P = 0.33)
(Figure 2A). There was low heterogeneity between the
three cohort studies (I2 = 8%; P = 0.34).
Three studies [55-57] examined the association of fas-
cin-1 positivity of carcinomas with lymph node metasta-
sis, with a total of 823 gastric carcinoma cases. Based on
the studies, the pooled fixed effects RR estimate was
1.43 (1.21 to 1.70; P <0.001) (Figure 4A). There was no
heterogeneity between the three cohort studies (I2 = 0%;
P = 0.5).
Two studies [55,57] examined the association of fas-
cin-1 positivity of carcinomas with distant metastasis,
with a total of 314 gastric carcinoma cases. Based on
the studies, the pooled fixed effects RR estimate was
1.93 (1.12 to 3.33; P = 0.02) (Figure 5A). There was no
heterogeneity between the two cohort studies (I2 = 0%;
P = 0.6).
Lung carcinoma
Two studies [50,53] examined the association of fascin-1
positivity of carcinomas with mortality, with a total of
293 lung carcinoma cases. Based on the studies, the
pooled fixed effects HR estimate was 0.78 (0.38 to 1.62;
P = 0.51) (Figure 2A). There was moderate heterogene-
ity between the two cohort studies (I2 = 42%; P = 0.2).
Two studies [50,53] examined the association of fas-
cin-1 positivity of carcinomas with time-to-disease
progression with a total of 293 lung carcinoma cases.
Based on the studies, the pooled fixed effects HR esti-
mate was 0.95 (0.49 to 1.85; P = 0.9) for mortality,
recurrence or metastasis outcomes (Figure 3). There was
no heterogeneity between the two cohort studies (I2 =
0%; P = 0.6).
Two studies [64,65] examined the association of fas-
cin-1 positivity of carcinomas with lymph node metasta-
sis, with a total of 147 lung carcinoma cases. Based on
the studies, the pooled random effects RR estimate was
3.11 (0.64 to 15.25; P = 0.2) (Figure 4A). There was
moderate heterogeneity between the two cohort studies
(I2 = 63%; P = 0.1).
Esophageal carcinoma
Four studies [7,9,58,59] examined the association of high
fascin-1 with mortality and one [60] examined the asso-
ciation of fascin-1 positivity of carcinomas with mortality,
with a total of 972 esophageal carcinoma cases. The study
examining fascin-1 positivity had a HR estimate of 1.38
(1.01 to 1.89; P = 0.05) (Figure 2A). Based on studies
examining high fascin-1, the pooled fixed effects HR esti-
mate was 1.33 (1.09 to 1.64; P = 0.01) (Figure 2B). Pool-
ing across all studies gave a fixed effects HR estimate of
1.35 (1.13 to 1.60; P = 0.001). There was moderate het-
erogeneity between studies that scored fascin-1 as high
versus low levels (I2 = 41%; P = 0.2) and moderate
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heterogeneity when all studies were pooled (I2 = 22.3%;
P = 0.27).
Two studies [8,60] examined the association of fascin-1
positivity of carcinomas with lymph node metastasis and
four [7,9,58,66] examined the association of high fascin-1
with lymph node metastasis, with a total of 1,103 esopha-
geal carcinoma cases. Based on studies examining fascin-1
positivity, the pooled fixed effects RR estimate was 1.57
(1.14 to 2.15; P = 0.01) (Figure 4A). Based on studies
examining high fascin-1, the pooled random effects RR
estimate was 1.04 (0.80 to 1.36; P = 0.77) (Figure 4B).
Pooling across all studies gave a random effects RR esti-
mate of 1.16 (0.91 to 1.49; P = 0.24). There was no hetero-
geneity between studies that scored fascin-1 as positive
versus negative (I2 = 0%; P = 0.4). There was moderate
heterogeneity between studies that scored fascin-1 as high
versus low levels (I2 = 69.1%; P = 0.02) or when all studies
were pooled (I2 = 68.1%; P = 0.008).
Two studies [9,58] examined the association of high
fascin-1 with distant metastasis and one [8] examined
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the association of fascin-1 positivity of carcinomas with
distant metastasis, with a total of 516 esophageal carci-
noma cases. The study examining fascin-1 positivity had a
RR estimate of 0.55 (0.04 to 8.37; P = 0.7) (Figure 5A).
Based on studies examining high fascin-1, the pooled fixed
effects RR estimate was 1.86 (0.97 to 3.56; P = 0.06)
(Figure 5B). Pooling across all studies gave a pooled fixed
effects RR estimate of 1.74 (0.92 to 3.28; P = 0.09). There
was no heterogeneity between studies that scored fascin-1
as high versus low levels (I2 = 0%; P = 0.8) or when all stu-
dies were pooled (I2 = 0%; P = 0.66).
Analysis of all included carcinomas
Eleven studies [19-21,50-53,55-57,60] examined the asso-
ciation of fascin-1 positivity of carcinomas with mortality
and seven studies [6,7,9,24,54,58,59] examined the asso-
ciation of high fascin-1 with mortality, with a total of
3,645 carcinoma cases. Based on studies examining fas-
cin-1 positivity, the pooled random effects HR estimate
was 1.46 (1.10 to 1.94; P = 0.008) (Figure 2A). Based on
studies examining high fascin-1, the pooled fixed effects
HR estimate was 1.46 (1.28 to 1.66; P <0.001) (Figure
2B). The overall pooled random effects HR estimate for
the association of fascin-1 with mortality was 1.44 (1.24
to 1.68; P <0.001). There was low heterogeneity between
studies that scored fascin-1 as high versus low levels (I2 =
16%; P = 0.31). There was moderate heterogeneity
between studies that scored fascin-1 as positive versus
negative (I2 = 50%; P = 0.03) or when all studies were
pooled (I2 = 37.4%; P = 0.06).
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Six studies [19,21,50-53] examined the association of
fascin-1 positivity with time-to-disease progression, with
a total of 928 carcinoma cases. The overall random
effects HR estimate for the association of fascin-1 with
time-to-disease progression was 1.82 (1.19 to 2.77; P =
0.006) for mortality, recurrence or metastasis outcomes
(Figure 3). There was moderate heterogeneity between
the studies (I2 = 49.4%; P = 0.08).
Ten studies [8,11,55-57,60-62,64,65] examined the asso-
ciation of fascin-1 positivity of carcinomas with lymph
node metastasis and seven studies [6,7,9,54,58,63,66]
examined the association of high fascin-1 with lymph
node metastasis, with a total of 2,906 carcinoma cases.
Based on studies examining fascin-1 positivity, the pooled
fixed effects RR estimate was 1.54 (1.37 to 1.73; P <0.001)
(Figure 4A). Based on studies examining high fascin-1, the
pooled random RR estimate was 1.12 (0.93 to 1.35; P =
0.25) (Figure 4B). The overall pooled random effects RR
estimate for the association of fascin-1 with lymph node
metastasis was 1.36 (1.18 to 1.55; P <0.001). There was no
heterogeneity between studies that scored fascin-1 as posi-
tive versus negative (I2 = 0%; P = 0.5). There was moderate
heterogeneity between studies that scored fascin-1 as high
versus low levels (I2 = 53.7%; P = 0.04 or when all studies
were pooled (I2 = 55.3%; P = 0.003).
Six studies [8,11,52,55,57,61] examined the association
of fascin-1 positivity of carcinomas with distant metastasis
and three studies [9,54,58] examined the association of
high fascin-1 with distant metastasis, with a total of 1,514
carcinoma cases. Based on studies examining fascin-1
positivity, the pooled fixed effects RR estimate was
1.76 (1.29 to 2.4; P <0.001) (Figure 5A). Based on studies
examining high fascin-1, the pooled fixed RR estimate was
1.78 (1.0 to 3.14; P = 0.05) (Figure 5B). The overall pooled
fixed effects RR estimate for the association of fascin-1
with distant metastasis was 1.76 (1.34 to 2.32; P <0.001).
There was no heterogeneity between studies that scored
fascin-1 as positive versus negative (I2 = 0%; P = 0.85),
between studies that scored fascin-1 as high versus low
levels (I2 = 0%; P = 0.92) or when all studies were pooled
(I2 = 0%; P = 0.98).
Subgroup analysis
To address if the variations in methodological quality of
the studies were possible sources of heterogeneity, we car-
ried out subgroup analysis by methodological quality
scores. For the 18 studies [6,7,9,19-21,24,50-60] which
examined the association of fascin-1 with mortality, 8 stu-
dies [6,7,9,24,52,55,56,58] with a high quality scores had a
pooled fixed effects HR estimate of 1.43(1.26 to 1.63;
P <0.001) (Table 1A), 2 studies [50,51] with quality scores
just below the threshold had a pooled random effects HR
estimate of 2.20 (0.77 to 6.34; P = 0.14) (Table 1A) and
8 studies [19-21,53,54,57,59,60] with poor quality scores
had a random effects HR of 1.48 (1.05 to 2.08; P = 0.03)
(Table 1A).
For the 6 studies [19,21,50-53] which examined the
association of fascin-1 with time-to-disease progression,
1 study [52] with a high quality score had a HR of 1.52
(1.04 to 2.23; P <0.05), 2 studies [50,51] with quality scores
just below the threshold had a pooled random effects HR
estimate of 1.91 (0.64 to 5.70; P = 0.25) (Table 1A) and
3 studies [19,21,53] with poor quality scores had a pooled
random effects HR estimate of 1.90 (0.81 to 4.46; P = 0.14)
(Table 1A).
For the 17 studies [6-9,11,54-58,60-66] which examined
the association of fascin-1 with lymph node metastasis,
6 studies [6,7,9,55,56,58] with high quality scores had a
pooled random effects RR estimate of 1.21 (0.97 to 1.51;
P = 0.09) (Table 1A) and 11 studies [8,11,54,57,60-66]
with poor quality scores had a pooled random effects RR
estimate of 1.47 (1.25 to 1.73; P <0.001) (Table 1A).
For the 9 studies [8,9,11,52,54,55,57,58,61] which
examined the association of fascin-1 with distant metas-
tasis, 4 studies [9,52,55,58] with high quality scores had
a fixed effects RR estimate of 1.81(1.28 to 2.57; P =
0.001) (Table 1A) and 5 studies [8,11,54,57,61] with
poor quality scores had a fixed effects RR estimate of
1.68 (1.08 to 2.62; P = 0.02) (Table 1A).
In addition, we grouped the studies according to
whether they had presented adjusted or unadjusted results.
Ten studies [6,7,9,24,51,52,54-56,58] presented multivari-
able results for the mortality outcome, with a total of
2,501 carcinoma cases. The overall pooled fixed effects HR
estimate was 1.44 (1.28 to 1.62; P <0.001) (Table 1B).
There was low heterogeneity between the studies (I2 =
21.7%; P = 0.24). Eight studies [19-21,50,53,57,59,60]
presented unadjusted results which included results from
univariable analysis and univariable Kaplan-Meier curves.
The overall pooled random effects HR estimate was 1.48
(0.97 to 2.26; P = 0.07) (Table 1B). There was moderate
heterogeneity between the studies (I2 = 55.3%; P = 0·03).
Sensitivity analysis
The analysis of all carcinomas indicated an association of
fascin-1 with increased risk of mortality. However, not all
studies had provided a clear definition of the cause of
death. Therefore, we carried out a sensitivity analysis that
included only studies [6,9,19,20,51,52,54,55,58,60] which
had provided a clear definition that “death” referred to
cancer-specific mortality. The result was consistent with
the analysis of all mortality outcomes (pooled fixed effects
HR = 1.49 (1.29 to 1.72); P <0.001) (Table 2A). A second
sensitivity analysis included only studies of patients with
stage III/IV colorectal carcinomas [6,24,51,52]. The result
(pooled fixed effects HR = 1.70 (1.42 to 2.03); P <0.001)
was consistent with the analyses of all stages of colorectal
carcinomas (Table 2B).
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Publication bias
We investigated for the potential presence of publication
bias through visual inspection of funnel plot asymmetry
and by computation of Egger’s test. For the mortality,
time-to-disease progression and distant metastasis out-
comes, data points in the funnel plot analyses approxi-
mated a symmetrical distribution indicating that
publication bias is unlikely to be present in our analyses
(Figure 6). For the lymph node metastasis outcome
Egger’s P-value for funnel plot asymmetry was 0.05.
Visual inspection of the funnel plot for lymph node
metastasis, (Figure 6), showed that two studies, [8,64],
were highly influential in the result of Egger’s asymmetry
test. After exclusion of these two studies, the data points
in the funnel plot analysis approximated a symmetrical
distribution with no evidence of bias (Egger’s test:
P = 0.27) (Additional file 3).
Discussion
The importance of demonstrating the reproducibility of
biomarker studies to validate their utility for the clinic is
increasingly well recognized [67]. Our systematic review
and meta-analysis is the first investigation of the overall
worldwide evidence on the association of the actin-bund-
ling protein fascin-1 with mortality, time-to-disease pro-
gression, lymph node metastasis and distant metastasis, in
some of the most prevalent forms of carcinoma.
Our meta-analyses demonstrate that there is strong
evidence that fascin-1 protein is associated with an up to
two and a half-fold increased risk of mortality in breast,
colorectal and esophageal carcinomas. At present, there
is little evidence that fascin-1 is associated with mortality
for gastric and lung carcinomas. Fascin-1 is correlated
with increased risk of disease progression in breast and
colorectal carcinomas, but not in lung carcinoma. Strong
Table 1 Subgroup analyses
Strata of analysis for each outcome Number of studies
included
HR/RR as appropriate (95% CI);
P-value
Heterogeneity
A. Methological quality scores
Mortality
Studies with a score of ≥6 points [6,7,9,24,52,55,56,58] 8 1.43 (1.26 to 1.63); P <0.001 I2 = 12.4%; P = 0.33
Studies with a score of 5 points [50,51] 2 2.20 (0.77 to 6.34); P = 0.14 I2 = 52.6%; P = 0.15
Studies with a score of <5 points [19-21,53,54,57,59,60] 8 1.48 (1.05 to 2.08); P = 0.03 I2 = 55.5%; P = 0.03
Time-to-disease progression
Study with a score of ≥6 points [52] 1 1.52 (1.04 to 2.23); P <0.05
Studies with a score of 5 points [50,51] 2 1.91 (0.64 to 5.70); P = 0.25 I2 = 77.4%; P = 0.04
Studies with a score of <5 points [19,21,53] 3 1.90 (0.81 to 4.46); P = 0.14 I2 = 54.9%; P = 0.11
Lymph node metatasis
Study with a score of ≥6 points [6,7,9,55,56,58] 6 1.21 (0.97 to 1.51); P = 0.09 I2 = 68.5%;
P = 0.007
Studies with a score of <5 points [8,11,54,57,60-66] 11 1.47 (1.25 to 1.73); P <0.001 I2 = 38.5%; P = 0.09
Distant metastasis
Studies with a score of ≥6 points [9,52,55,58] 4 1.81 (1.28 to 2.57); P = 0.001 I2 = 0.0%; P = 0.99
Studies with a score of <5 points [8,11,54,57,61] 5 1.68 (1.08 to 2.62); P = 0.02 I2 = 0.0%; P = 0.74
B. Adjusted versus unadjusted results for Mortality
Studies with results from multivariable analysis
[6,7,9,24,51,52,54-56,58]
10 1.44 (1.28 to 1.62); P <0.001 I2 = 21.7%; P = 0.24
Studies without results from multivariable analysis
[19-21,50,53,57,59,60]
8 1.48 (0.97 to 2.26); P = 0.07 I2 = 55.3%; P = 0.03
Note: Time-to-disease progression is defined by the occurrence of the outcomes time-to-mortality, recurrence or metastasis.
Table 2 Sensitivity analyses
Strata of analysis for each outcome Number of studies
included
HR (95% CI); P-value Heterogeneity
A. Studies with definition for cancer specific mortality included
[6,9,19,20,51,52,54,55,58,60]
10 1.49 (1.29 to 1.72); P <0.001 I2:23.4%; P =
0.23
B. Only Stage III/IV colorectal carcinoma studies included
[6,24,51,52]
High versus Low: 2 High versus Low: 1.64 (1.34 to 2.00); P
<0.001
I2: 0%; P = 0.38
Positive versus
Negative: 2
Positive versus Negative: 1.95 (1.32 to
2.87); P = 0.001
I2: 46.7%; P =
0.17
Overall colorectal
studies: 4
Overall colorectal studies: 1.70 (1.42 to
2.03); P <0.001
I2: 7.2%; P =
0.36
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evidence for association of fascin-1 with increased risk of
lymph node metastasis was found for colorectal and gas-
tric carcinomas, but not for lung and esophageal carcino-
mas. Fascin-1 protein was also associated with a greater
than 70% increased risk of distant metastasis in colorec-
tal, gastric and esophageal carcinomas, although the sta-
tistical evidence for association with esophageal
carcinoma metastasis was weak.
The potential for search and inclusion bias in our meta-
analysis is considerably reduced as we conducted a com-
prehensive search of four databases for papers published
in all languages. Publication bias could result from selec-
tive reporting of results by individual studies, because sta-
tistically insignificant results are often not published
[68,69]. Many authors did not respond to requests for
information or clarification and we also identified several
studies which did not report all their data. However,
funnel plot analyses were not generally indicative of any
strong publication bias because visual inspection of funnel
plots did not show asymmetry (Figure 6). There was
potential for misclassification of outcome, because some
studies did not provide a clear definition of the cause of
death. However, sensitivity analysis of studies that had
provided a clear definition of cancer-specific mortality
demonstrated that fascin-1 expression was associated with
a 49% increased risk of cancer-specific death. This effect-
estimate was similar to the pooled results from studies
that did not have a clear definition of the cause of death
(Table 2A).
All esophageal carcinoma studies included in our meta-
analysis were carried out in Asia. Esophageal carcinoma
shows marked geographic variation with exceptionally
high rates in Asia [70]. However, rates of esophageal ade-
nocarcinomas are increasing rapidly in several Western
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countries [71]. To exclude ethnicity and locality as modi-
fying factors, more studies should be carried out to assess
the association between fascin-1 and risk of esophageal
cancer-specific mortality in Western countries.
All the included studies used immunohistochemical
analysis of archived tumor specimens to quantify fascin-
1. Immunohistochemistry is a pathologist-based scoring
system that is the most commonly used and reliable
technique in diagnostic histopathology [72]. In addition,
nearly all included studies used the same two antibodies
to fascin-1, enabling comparability of prognostic effects
in our meta-analysis. Only one cohort [24] was prospec-
tively assembled. The remaining studies were retrospec-
tive in design using samples based on the availability of
specimens with interpretable cores (which may have
been non-random) and clinical histories, rather than
specifying and recruiting a truly representative sample
from a clearly defined target population. No studies pro-
vided an appropriate justification of the sample size or a
power calculation. In addition, there was limited control
for confounding in the analysis of most datasets and
incomplete ascertainment of outcome data, due to loss
to follow-up, which can lead to biased effect-estimates.
Therefore, most of the studies included in our meta-
analysis were assessed as having a risk of bias. For the
18 studies examining associations of fascin-1 with mor-
tality, only 8 studies, [6,7,9,24,52,55,56,58], were found
to be of high methodological quality. We were some-
what reassured, however, that the high quality studies
showed a positive association between fascin-1 expres-
sion and mortality (pooled fixed effects HR: 1.43 (1.26
to 1.63; P <0.001), that was similar in magnitude to the
association observed when all 18 studies were pooled
(pooled random effects HR: 1.44 (1.24 to 1.68; P <0.001).
The scoring of fascin-1 by immunohistochemistry is a
continuous measurement and in most publications
researchers categorized tumor specimens into high/posi-
tive fascin-1 or low/negative fascin-1 based on different
semi-quantitatively assessed cut-off points. For example,
two studies [58,66] categorized 0 to 8 as low expression
and 9 to 12 as high expression.
On the other hand, another study [9] dichotomized
low expression as a score of <75% immunoreactive
tumor cells and high expression as >75% immunoreac-
tive tumor cells. These differences could possibly discard
potentially important quantitative information and
reduce statistical power to detect real associations [73].
There was also qualitative evidence of heterogeneity
between the individual studies, but based on the number
of available studies for each carcinoma type, it was not
possible to investigate this statistically using meta-
regression (apart from stratifying by scoring method).
However, a recent meta-analysis of other immunohisto-
chemical prognostic markers demonstrated that the cut-
off value of the percentage of positively-stained cells used
in the scoring criteria appears unlikely to bias the underly-
ing relationship between a prognostic biomarker and mor-
tality [74]. With regard to future studies of fascin-1, our
analyses indicate that scoring of tumors as fascin-1 nega-
tive (taken either as completely absent [52,61], below 5%
fascin-1 positive cells within a tumor [21,50,53,55-57,
60,64], or below 10% fascin-1 positive cells within a tumor
[19,20,51,62]) versus fascin-1 positive (that is, either more
than 5% or 10% fascin-1 positive cells within a tumor) is
adequate to detect an association of fascin-1 with risk of
mortality (Figure 2). The validity of this simple scoring
metric should facilitate clinical application of fascin-1 as a
biomarker.
Metastasis is the major source of cancer-related mor-
tality and, at the cellular level, a major effect of fascin-1 is
in promoting carcinoma cell migration and invasion. Pro-
motion of metastasis by fascin-1 has been reported in
several mouse tumor xenograft models [10-13]. Pooling
across all the included carcinomas in our dataset, we
obtained strong evidence that fascin-1 is associated with
increased risk of mortality, lymph node metastasis and
distant metastasis. However, there was evidence of het-
erogeneity between different carcinomas. This could be
expected due to the biological differences in mechanisms
of carcinoma progression for different organs. For exam-
ple, the weak association between fascin-1 and metastasis
in esophageal carcinomas could be due to the rapid pro-
gression to metastatic disease that occurs in most
patients with esophageal carcinoma. This is due to the
unique anatomy of the esophagus which lacks serosa,
thus making it easier for early rapid tumor cell spread
through the extensive network of lymph nodes [75,76].
This disease course is very different from that of breast
or colon carcinomas that develop through distinct stages
to an aggressive phenotype over many years.
Heterogeneity was also apparent within carcinoma types.
The three breast carcinoma studies showed evidence of
heterogeneity for mortality (I2 = 31.4%). However, it
should be noted that each study included different histolo-
gical types of breast carcinomas. Yoder et al. [19] studied
primary node-positive and node-negative invasive breast
carcinomas, which included infiltrating ductal carcinomas,
infiltrating lobular carcinomas, mucinous carcinomas
and medullary carcinomas. Al-Alwan et al. [21] studied
invasive ductal carcinoma only, and Rodriguez-Pinilla
et al. [20] investigated node-negative sporadic and heredi-
tary invasive breast carcinomas. As breast cancer is a
clinically heterogeneous disease [77], the heterogeneity
identified in the meta-analysis could be due to the pool-
ing of results across different subtypes of breast carcino-
mas. Further analyses of the association of fascin-1 with
breast cancer mortality or metastasis will need to specifi-
cally evaluate different sub-types of breast carcinomas.
Tan et al. BMC Medicine 2013, 11:52
http://www.biomedcentral.com/1741-7015/11/52
Page 13 of 17
In contrast, all the esophageal carcinoma studies had
analyzed squamous cell carcinomas (Additional file 2);
thus the between study heterogeneity is not due to pool-
ing of results across biologically different tumors within
the same organ.
Heterogeneity was also evident between the lung carci-
noma studies (I2 = 41.9%). All the studies in our dataset
had analyzed only non-small cell lung carcinomas, which
include both squamous cell carcinomas and adenocarcino-
mas. Patients with pulmonary squamous cell carcinoma
have a higher mortality rate than those with adenocarcino-
mas, which might be attributable to confounding factors,
such as smoking status and age-related co-morbidities
[78,79]. Adenocarcinomas include different subtypes such
as acinar, papillary, bronchioalveolar carcinoma and ade-
nocarcinomas with mixed subtypes, which could account
for the histological heterogeneity. One study reported that
fascin-1 immuno-staining was more common in adenocar-
cinomas with prevalent invasive components of the acinar,
papillary and solid types compared to adenocarcinomas
with a prevalent bronchiolo-alveolar component [50].
Thus, the observed heterogeneity in these studies could be
due to differences in fascin-1 immunostaining among dif-
ferent subtypes of adenocarcinomas.
Differences in patient selection and disease etiology could
also explain the heterogeneity between studies of colorectal
carcinomas. Most analyses included all stages of colorectal
carcinomas in their specimen sets [6,11,48,54,61-63], never-
theless, multiple studies reported important correlations of
fascin-1 expression with increased mortality for stage III
and IV tumors [6,24,51,52], as confirmed by our sensitivity
analysis results (Table 2B). Historically, the majority of
colon adenocarcinomas originate in the left (distal) colon,
yet the prevalence of right-sided (proximal) tumors is
increasing [80] and multiple studies correlated high fascin-
1 expression with right-sided (proximal) colonic tumors
[6,24,61,62]. In addition, rectal carcinomas have different
biological, clinicopathologic and therapeutic implications
from colon carcinomas [52,81]. It would be preferable for
future studies to analyze the association of fascin-1 with
colorectal carcinomas specifically within stages and accord-
ing to tumor location [24,52].
For our meta-analysis of the association of fascin-1 with
mortality, we extracted multivariable analysis results from
most studies, except one, [59], which presented univariable
analysis results and seven studies, [19-21,50,53,57,60],
which presented results as univariable Kaplan-Meier
curves. Subgroup analysis of studies that presented multi-
variable analysis results showed that fascin-1 protein was
associated with a 44% increased risk of mortality. Ideally,
meta-analysis would be based on the data of individual
patients to allow for standardized control for confounding
across all studies [82]. As the hazard ratios from different
studies have been adjusted for different confounders, we
were unable to assess the independent role of fascin-1 as a
new marker over existing markers [68].
Conclusions
Our meta-analysis study demonstrates that fascin-1 is
associated with increased risk of mortality in breast, color-
ectal and esophageal carcinomas and with increased risk
of metastasis in colorectal and gastric carcinomas. The
results were stable to a variety of sensitivity analyses and
did not vary by predefined subgroups. Due to limitations
of the individual studies to date (issues of methodological
quality due to retrospective study designs, inadequate sam-
ple size or power justification, possible biases due to selec-
tive reporting and heterogeneity in study methodologies),
adequately powered prospective studies, particularly in
breast, colorectal, gastric and esophageal carcinomas, will
be needed to fully determine the relative independent
prognostic impact of fascin-1. Pooled analysis of all carci-
nomas within our dataset provides strong evidence that
fascin-1 may have potential as a novel biomarker for early
identification of aggressive and metastatic tumors. These
data will assist rational decision making for focusing on-
going efforts investigating fascin-1 as a biomarker onto the
most relevant carcinomas.
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